Quantcast

Latest Drug repositioning Stories

2014-06-26 16:23:38

Paper Addresses Challenges and Explores Opportunities to Stimulate Repurposing of FDA-Approved Drugs for Alzheimer's, Parkinson's and Related Diseases NEW YORK, June 26, 2014 /PRNewswire-USNewswire/ -- A new peer-reviewed publication from the Alzheimer's Drug Discovery Foundation (ADDF) and The Michael J. Fox Foundation for Parkinson's Research (MJFF) offers strategic insight on how philanthropy, industry and government organizations can advance repurposing of U.S. Food and Drug...

2011-05-05 09:17:00

CHARLOTTESVILLE, Virginia and ATHENS, Greece, May 5, 2011 /PRNewswire/ -- Biovista Inc. announced today that it's EU affiliate has been awarded a prestigious grant worth $0.5 million, for research and development in the area of personalized medicine. The "p-medicine" project is a four-year, 13.3 million Euro co-funded effort under the European Community's 7th Framework Programme that aims to develop new tools, infrastructure and VPH (Virtual Physiological Human) models in order to help...

2010-11-09 08:33:00

CHARLOTTESVILLE, Virginia, November 9, 2010 /PRNewswire/ -- Biovista announced today that it has entered into a pilot research collaboration agreement with Pfizer (Pfizer Inc. (NYSE: PFE). The aim of the collaboration is to identify new indications for a number of undisclosed Pfizer development candidates, using Biovista's Clinical Outcome Search Space (COSS) technology. Under the terms of the agreement, Biovista will collaborate with Pfizer's Indications Discovery Unit to identify...

2009-12-16 08:00:00

CHARLOTTESVILLE, Virginia, December 16 /PRNewswire/ -- Biovista Inc. today announced that it was awarded the 2009 Top Innovator Presentation Award in Healthcare, at the 2009 New England Venture Summit, held on December 8th at Dedham, MA. The award, which recognizes cutting edge private companies driving the future of innovation, was granted to Biovista who competed with over 50 other privately held companies that play a leading role in innovation in the Technology, Life Sciences and...

2008-08-01 09:01:04

Ore Pharmaceuticals has acquired from Roche the clinical-stage compound tiapamil. The company had previously identified potentially novel therapeutic uses for tiapamil in central nervous system disease and recently filed for patent protection regarding the use of the compound. Ore Pharmaceuticals analyzed and subsequently acquired the compound as part of the previously announced drug repositioning partnership agreement with Roche. Tiapamil had reached Phase II or Phase III clinical testing...

2008-07-31 06:00:55

Ore Pharmaceuticals Inc. (NASDAQ:ORXE) announced today that it has acquired from Roche the clinical-stage compound tiapamil. Ore Pharmaceuticals had previously identified potentially novel therapeutic uses for tiapamil in central nervous system (CNS) disease and recently filed for patent protection regarding the use of the compound. The Company plans to further develop tiapamil, and will select the most appropriate of several potential indications, prepare for Phase II clinical trials, and...

2008-06-24 18:02:47

Melior Discovery, Inc. announced today that it has signed an option agreement that provides Pfizer Inc the exclusive right to negotiate a license to MLR-1023, Melior's drug candidate for Type II diabetes. In exchange, Pfizer agreed to make an undisclosed payment to Melior and provide access to certain data it owns related to MLR-1023. In addition, Melior agreed to utilize its in-vivo theraTRACE(R) indications discovery platform to evaluate the activity of selected Pfizer compounds in...


Word of the Day
tessitura
  • The prevailing range of a vocal or instrumental part, within which most of the tones lie.
This word is Italian in origin and comes from the Latin 'textura,' web, structure.